{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:27:13Z","timestamp":1777840033056,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Apidel SA","award":["2014\/1"],"award-info":[{"award-number":["2014\/1"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jconrel.2017.07.044","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T03:01:31Z","timestamp":1501556491000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Self-assembling polymeric nanocarriers to target inflammatory lesions in ulcerative colitis"],"prefix":"10.1016","volume":"275","author":[{"given":"Herve","family":"Courthion","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Mugnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Rousseaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gurny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2017.07.044_bb0005","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.crohns.2007.06.005","article-title":"Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey","volume":"1","author":"Ghosh","year":"2007","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.jconrel.2017.07.044_bb0015","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ibd.20301","article-title":"Quality of life of patients with ulcerative colitis: past, present, and future","volume":"14","author":"Irvine","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11894-015-0444-2","article-title":"Next-generation therapeutics for IBD","volume":"17","author":"L\u00f6wenberg","year":"2015","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/1756283X14558193","article-title":"Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases","volume":"8","author":"Amiot","year":"2015","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0030","doi-asserted-by":"crossref","first-page":"11343","DOI":"10.3748\/wjg.v21.i40.11343","article-title":"Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease","volume":"21","author":"Takedatsu","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0035","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.crohns.2014.02.024","article-title":"Nanotechnology in the treatment of inflammatory bowel diseases","volume":"8","author":"Viscido","year":"2014","journal-title":"J. Crohns Colitis."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2012.01.028","article-title":"Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa","volume":"161","author":"Collnot","year":"2012","journal-title":"J. Control. Release"},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2017.07.044_bb0045","first-page":"S55","article-title":"Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases","volume":"7","author":"Ulbrich","year":"2010","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.jconrel.2017.07.044_bb0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2012.10.019","article-title":"Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients","volume":"165","author":"Schmidt","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.07.044_bb0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2014.10.026","article-title":"Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse","volume":"197","author":"Maisel","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.07.044_bb0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/MOG.0b013e32816aa392","article-title":"Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications","volume":"23","author":"Mankertz","year":"2007","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1196\/annals.1326.017","article-title":"Inflammatory bowel disease and the apical junctional complex","volume":"1072","author":"Bruewer","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0075","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1021\/mp9000926","article-title":"Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa","volume":"6","author":"Tirosh","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0080","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.dld.2007.05.010","article-title":"Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype","volume":"39","author":"Meijer","year":"2007","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0085","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.2042-7158.1985.tb04992.x","article-title":"Drug delivery to the proximal colon","volume":"37","author":"Hardy","year":"1985","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0090","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.3748\/wjg.v20.i29.9675","article-title":"Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease","volume":"20","author":"Renna","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jconrel.2013.04.019","article-title":"In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application","volume":"170","author":"Rodriguez-Aller","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.07.044_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1519s49","article-title":"Induction of TNBS colitis in mice","author":"Scheiffele","year":"2002","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0105","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1167\/iovs.11-8829","article-title":"A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation","volume":"53","author":"Di Tommaso","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2017.07.044_bb0110","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.7869\/tg.281","article-title":"Cyclosporine in steroid refractory acute severe colitis","volume":"35","author":"Kumar","year":"2014","journal-title":"Trop. Gastroenterol."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00384-012-1602-8","article-title":"Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis","volume":"28","author":"Chang","year":"2013","journal-title":"Int. J. Color. Dis."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4292\/wjgpt.v1.i5.87","article-title":"Novel topical therapies for distal colitis","volume":"1","author":"Lawrance","year":"2010","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0125","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1023\/A:1015339018181","article-title":"Effect of cyclosporine in a murine model of experimental colitis","volume":"47","author":"Bani\u0107","year":"2002","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0130","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1007\/BF01303184","article-title":"Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin","volume":"38","author":"Murthy","year":"1993","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0135","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3109\/00365529309098276","article-title":"Cyclosporin A retention enemas in refractory distal ulcerative colitis and \u201cpouchitis\u201d","volume":"28","author":"Winter","year":"1993","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0140","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/0016-5085(94)90394-8","article-title":"A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis","volume":"106","author":"Sandborn","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2017.07.044_bb0145","first-page":"640","article-title":"Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis","volume":"88","author":"Sandborn","year":"1993","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/j.1552-4604.1991.tb01890.x","article-title":"The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration","volume":"31","author":"Sandborn","year":"1991","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0155","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijpharm.2016.03.012","article-title":"Cyclosporine A loaded lipid nanoparticles in inflammatory bowel disease","volume":"503","author":"Guada","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2017.07.044_bb0160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.52.2.172","article-title":"Cyclosporine for refractory ulcerative colitis","volume":"52","author":"Loftus","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2017.07.044_bb0165","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0022-3565(24)29290-9","article-title":"Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease","volume":"299","author":"Lamprecht","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0170","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s11095-005-5376-3","article-title":"Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model","volume":"22","author":"Kesisoglou","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0175","doi-asserted-by":"crossref","first-page":"300ra128","DOI":"10.1126\/scitranslmed.aaa5657","article-title":"An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease","volume":"7","author":"Zhang","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0180","unstructured":"H. Courthion, M. Moeller, R. Gurny, D. Gabriel, Upscaling the manufacturing of drug loaded self-assembling nanocarriers, Nanomed. Nanotechnol. Biol. Med. (submitted)."},{"key":"10.1016\/j.jconrel.2017.07.044_bb0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpb.2010.09.012","article-title":"Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study","volume":"77","author":"Mondon","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917307642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917307642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:33:58Z","timestamp":1759160038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365917307642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":37,"alternative-id":["S0168365917307642"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.07.044","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-assembling polymeric nanocarriers to target inflammatory lesions in ulcerative colitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.07.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}